UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 8, 2002
----------------------------
TRIANGLE PHARMACEUTICALS, INC.
-------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-21589 56-1930728
-------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 493-5980
-----------------------------
-------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits.
(c) Exhibits. The following document is incorporated by reference to this
Report:
99.1 Officer Certifications dated November 8, 2002 pursuant to the
Sarbanes-Oxley Act of 2002.
Item 9. Regulation FD Disclosure.
In accordance with General Instruction B.2. of Form 8-K, the following
information shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended.
On November 8, 2002, the Chairman and Chief Executive Officer and the
Chief Financial Officer of Triangle Pharmaceuticals, Inc. submitted to the
Securities and Exchange Commission certifications pursuant to the
Sarbanes-Oxley Act of 2002 in connection with the Form 10-Q of Triangle
Pharmaceuticals, Inc. for the period ended September 30, 2002. Copies of
these certifications are attached hereto as Exhibit 99.1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Triangle Pharmaceuticals, Inc.
------------------------------------------
(Registrant)
November 8, 2002 /s/ Daniel G. Welch
------------------------------- ------------------------------------------
Date (Signature)
Name: Daniel G. Welch
Title: Chairman & Chief Executive Officer